ZYGEL

What this means for you

Not registered yet, but its 14 Aug 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.

Record

Serial number

98130731

Mark type

Design + words

Filed

14 Aug 2023

Attorney of record

Sarah Anne Keefe

Goods and services

• Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of human and veterinary diseases and disorders, namely, addiction, auditory diseases and disorders, autism, autoimmune diseases and disorders, anxiety, bone diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, cognitive diseases and disorders, dermatological diseases and disorders, diabetic diseases and disorders, endocrine diseases and disorders, gastroenterological diseases and disorders, genetic diseases and disorders, genitourinary diseases and disorders, hepatological diseases and disorders, hormonal diseases and disorders, infectious diseases and disorders, immunological diseases and disorders, inflammatory diseases and disorders, metabolic diseases and disorders, movement diseases and disorders, muscular diseases and disorders, musculoskeletal diseases and disorders, neurodegenerative diseases and disorders, neurodevelopmental diseases and disorders, oncological diseases and disorders, ophthalmic diseases and disorders, pain, post-traumatic stress, pulmonary diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, rheumatological diseases and disorders, psychiatric diseases and disorders, seizure diseases and disorders, sexual dysfunction, speech disorders and diseases, traumatic brain injury, and viral diseases and disorders; Pharmaceutical preparations for the treatment of fragile x syndrome, substance related addiction, autism and autism spectrum disorders, epilepsy, seizure diseases and disorders, anxiety, aphasias, stuttering, post-traumatic stress disorder; all of the foregoing specifically excluding narcolepsy and management of sleep disorders and all of the foregoing solely derived from manufactured synthetic cannabidiol and which do not contain delta-9 tetrahydrocannabinol (THC)

Owner

• Zynerba Pharmaceuticals, Inc., Devon, PA, US

Prosecution history

• 30 Oct 2025 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
• 30 Oct 2025 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
• 07 Oct 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 07 Oct 2025 — NON-FINAL ACTION E-MAILED
• 07 Oct 2025 — NON-FINAL ACTION WRITTEN
• 11 Mar 2024 — TEAS/EMAIL CORRESPONDENCE ENTERED
• 11 Mar 2024 — CORRESPONDENCE RECEIVED IN LAW OFFICE
• 11 Mar 2024 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
• 05 Jan 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 05 Jan 2024 — NON-FINAL ACTION E-MAILED
• 05 Jan 2024 — NON-FINAL ACTION WRITTEN
• 02 Oct 2023 — ASSIGNED TO EXAMINER
• 27 Sept 2023 — ASSIGNED TO EXAMINER
• 20 Sept 2023 — ASSIGNED TO EXAMINER
• 14 Sept 2023 — NOTICE OF DESIGN SEARCH CODE E-MAILED